No Detail Found!

Seroprevalence of SARS-CoV-2 (COVID-19) antibodies in Tertiary Care Hospital of Karachi, Pakistan

Author(s)
Ambreen Fatima Department of Pathology, Dow International Medical College,Karachi,Pakistan
Fatima Fasih Department of Pathology, Dow International Medical College,Karachi,Pakistan
Samina Baig Department of Pathology, Dow International Medical College,Karachi,Pakistan
Fouzia Zeeshan Khan Department of Pathology, Dow International Medical College,Karachi,Pakistan
Saima Naseem Department of Pathology, Dow International Medical College,Karachi,Pakistan
Muhammad Asif Qureshi Department of Pathology, Dow International Medical College,Karachi,Pakistan
Abstract
Objective: To find the trend of seropositivity of antiSARS-CoV-2 antibodies in registered patients for COVID-19 in Dow Diagnostic Reference and Research laboratory Methodology: A total of 5247 patients were enrolled for SARS CoV2 antibodies analysis from 01 August to 31 December, 2020. Patient consent was attained and questionnaire forms were filled. Samples were tested for anti-SARS-CoV-2 antibodies on (Roche Cobase 601). Results: In 5247 patient's samples, seropositivity of SARS CoV2 was found in 2425 (46.2%) samples. Seroprevalence in males was 28.4% (n; 1491) as compared to females, who showed 17% (n; 934). The age group G3 (> 46 to 60 years) showed higher seropositivity (n = 604/1118, 54%) as related to other age groups. Out of total reactive patients, only 30% (n; 727) reported recent symptoms while 70% (n; 1697) were asymptomatic. Fever was observed to be the most common symptom followed by dry cough. The most commonly affected areas were East 2353 (44%), South 855 (16.01%), Malir 793 (14.85%), Center zone 589 (11.03%) and Korangi area 378 (7.08%). The frequency of seropositivity showed an increasing pattern in the six months from August 2020 to December 2020. It was found to be 11.5% in August, 13.6% in September, 13.9% in October, and 42.5% in December 2020. Conclusion: The trend of seropositivity revealed a gradual upward course in the duration of study period. Nearly, two thirds of the patients were asymptomatic indicating the fact that many individuals were silently exposed to the infection and developed antibodies through their natural defense mechanism.
Publication Details
Page(s) 70-73
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 48, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
SARS-CoV-2, COVID-19, Seroprevalence, antibody.
References
Al-Qahtani AA .2020 .Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): emergence, history, basic and clinical aspects. Saudi J Biol Sci, 27 : 2531-8.
. .. Health Advisory Platform by Ministry of National Health Services Regulations and Coordination, 08 : .
Malik YA .2020 .Properties of coronavirus and SARS-CoV-2. Malays J Pathol, 42 : 3-11.
Zaidi S,Rizwan F,Riaz Q,Siddiqui A,Khawaja S,Imam M .2021 .Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19. J Public Health, 43 : 3-8.
Zhou P,Yang XL,Wang XG,Hu B,Zhang L,Zhang W .2020 .A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579 : 270-3.
Liu B,Li M,Zhou Z,Guan X,Xiang Y. .2020 .Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS. J Autoimmun, 111 : 102452.
Wang Y,Wang Y,Chen Y,Qin Q. .2020 .Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol, 92 : 568-76.
Aziz KM,Othman A,Alqahtani W .2021 .Factors affecting SARS-CoV-2 (COVID-19) Pandemic, including Zoonotic, Human Transmission and Chain of Infection. Reducing Public health Risk by Serum Antibody Testing, Avoiding Screening in Unhygienic Places and False PCR Reporting. Iberoam J Med, 3 : 138-60.
Stringhini S,Wisniak A,Piumatti G,Azman AS,Lauer SA,Baysson H .2020 .Seroprevalence of anti-SARS-CoV2 IgG antibodies in Geneva, Switzerland (SEROCoVPOP): a population-based study. Lancet, 396 : 313-9.
Chughtai OR,Batool H,Khan MD,Chughtai AS .2020 .Frequency of COVID-19 IgG antibodies among special police squad Lahore, Pakistan. J Coll Physicians Surg Pak, 30 : 735-9.
Nisar MI,Ansari N,Khalid F,Amin M,Shahbaz H,Hotwani A .2021 .Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan. Int J Infect Dis, 106 : 176-82.
Megasari NL,Utsumi T,Yamani LN,Gunawan E,Furukawa K,Nishimura M .2021 .Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS One, 16 : e0251234.
Afzal N,Tariq N,Shakeel D,Sultan S. .2021 .Trend of AntiSARS-COV-2 Seropositivity in Karachi. Nat J Health Sci, 5 : 104-8.
Pollán M,Pérez-Gómez B,Pastor-Barriuso R,Oteo J,Pérez-Olmeda M,Yotti R .2020 .SARS-CoV-2 seroprevalence in Spain-Authors' reply. Lancet, 396 : 1484-5.
Haq M,Rehman A,Ahmad J,Zafar U,Ahmed S,Khan MA .2021 .SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?. Infection, 49 : 983-8.
Tahir S,Tahir SA,Arif TB,Majid B,Majid Z,Malik F .2020 .Epidemiological and clinical features of SARSCoV-2: a retrospective study from East Karachi, Pakistan. Cureus, 12 : e8679.
Wu Z,McGoogan JM .2020 .Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 323 : 1239-42.
Oran DP,Topol EJ .2020 .Prevalence of asymptomatic SARSCoV-2 infection: a narrative review. Ann Intern Med, 173 : 362-7.
Burgess S,Ponsford MJ,Gill D.,BMJ D. .2020 .Are we underestimating seroprevalence of SARS-CoV-2. , 370 : m3364.
0

Citations

0

Downloads

26

Views